Unmet need: What justifies the search for a new antidepressant?

Journal of Clinical Psychiatry

Volumn 63, Issue SUPPL. 2, 2002, Pages 3-7

  Greden, John F ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

BRAIN ATROPHY; CHRONIC DISEASE; CONFERENCE PAPER; DEPRESSION; DRUG INDUCED DISEASE; HIPPOCAMPUS; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; STRESS; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; ATROPHY; CHRONIC DISEASE; DEPRESSIVE DISORDER; DRUG INDUSTRY; DRUG RESISTANCE; HIPPOCAMPUS; HUMANS; PATIENT COMPLIANCE; RECURRENCE; RESEARCH; TECHNOLOGY, PHARMACEUTICAL; TREATMENT OUTCOME;

EID: 0036192893     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. The burden of disease for treatment-resistant depression
2. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
3. Depression in the workplace: Effects on short-term disability
4. Depression in the community: The first pan-European study DEPRES (Depression Research in European Society)
5. The longitudinal course of recurrent affective illness: Life chart data from research patients at the NIMH
6. The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders
7. Recurrent depression: Its overwhelming burden
8. Hippocampal atrophy in recurrent major depression
9. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders
10. Environment enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective
11. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
12. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: Implications for pathophysiology and treatment of manic-depressive illness
13. Neural plasticity to stress and antidepressant treatment
14. Early onset of antidepressant action: Impact on primary care
15. Pharmacologic characteristics of ideal antidepressants in the 21st century
16. The role of the primary care physician in patients' adherence to antidepressant therapy
17. Stepped collaborative care for primary care patients with persistent symptoms of depression
18. Factors contributing to failed trials of new agents: Can technology prevent some problems?
19. Depressive breakthrough
20. Beyond monoamine-based therapies: Clues to new approaches